Larger stakes, more newcos as Canaan moves to bump up biopharma investments with new $800M fund

With 40% of its new $800 million fund dedicated to healthcare, Canaan plans to ramp up biopharma investments and de novo company formation as it seeks larger ownership stakes.

“Given the increased capital going into the biopharma sector as a whole and our focus on higher ownership and seeking outsized returns, you’ll see us put an overall higher allocation — three-quarters to 80% of our healthcare investments — in biopharma,” Canaan Partners’ Nina Kjellson told BioCentury. ...